Journal
IMMUNOTHERAPY
Volume 8, Issue 8, Pages 853-866Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0023
Keywords
atopic dermatitis; Crisaborole Topical Ointment, 2%; cytokine; inflammation; pharmacokinetics; phosphodiesterase 4 inhibitor; pruritus; quality of life; topical calcineurin inhibitor; topical corticosteroid
Categories
Funding
- Anacor
- Ascend Biopharmaceuticals
- Astellas
- Australian Wool Innovation Limited
- Dermira
- Genentech
- GlaxoSmithKline
- Trius
- Abbott
- Novartis
- Janssen-Cilag
- Anacor Pharmaceuticals, Inc.
Ask authors/readers for more resources
Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of patients presenting with mild to moderate disease. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical anti-inflammatory PDE4 inhibitor currently being investigated for the treatment of mild to moderate AD. Preliminary studies in children and adults demonstrated favorable efficacy and safety profiles. Crisaborole may represent an anti-inflammatory option that safely minimizes the symptoms and severity of AD and that can be used for both acute and long-term management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available